论文部分内容阅读
[目的]分析放疗同步口服希罗达治疗局部晚期及术后复发直肠癌的近期疗效和毒副作用。[方法]经病理证实的局部晚期直肠癌患者23例及术后复发的直肠癌25例,随机分成2组,治疗组24例行常规三野等中心照射,并在放疗同时每天口服希罗达1650mg/m2,从放射治疗第1d开始,每周5次,直到放射治疗结束。对照组24例仅行单纯常规三野等中心照射。治疗结束后3个月复查盆腔CT观察近期疗效。[结果]治疗组总有效率为87.5%,对照组总有效率为58.3%,差异有统计学意义(P<0.05)。两组不良反应均主要为Ⅰ～Ⅱ度,仅治疗组1例患者发生Ⅲ度白细胞下降,但可耐受。[结论]放疗同步希罗达治疗局部晚期及术后复发直肠癌疗效确切,不良反应可耐受。
[Objective] To analyze the short-term curative effect and toxicity of concurrent oral Xeloda in the treatment of locally advanced and postoperative recurrent rectal cancer. [Methods] Twenty-three patients with locally advanced rectal cancer confirmed by pathology and 25 patients with recurrent rectal cancer after operation were randomly divided into two groups. 24 patients in the treatment group were treated with conventional San Ye et al. Radiotherapy was given simultaneously with 1650 mg of Xeloda / m2, starting from the first day of radiotherapy 5 times a week, until the end of radiotherapy. Control group, 24 cases only simple routine San Ye Center irradiation. Three months after treatment, pelvic CT review of the short-term efficacy. [Results] The total effective rate was 87.5% in the treatment group and 58.3% in the control group, the difference was statistically significant (P <0.05). Two groups of adverse reactions are mainly Ⅰ ~ Ⅱ degree, only one patient in the treatment group Ⅲ leukopenia occurs, but can be tolerated. [Conclusion] Radiotherapy of Xeloda in the treatment of locally advanced and postoperative recurrent rectal cancer is effective and the adverse reactions are tolerable.